Gabexate mesilate ameliorates the neuropathic pain in a rat model by inhibition of proinflammatory cytokines and nitric oxide pathway
Analgesia
Gabexate
Human
Hyperalgesia
Inflammation
NF-Kappa B
Neuralgia
Nitric Oxide Synthase Type II
Spinal Nerves
Journal
The Korean journal of pain
ISSN: 2005-9159
Titre abrégé: Korean J Pain
Pays: Korea (South)
ID NLM: 101528125
Informations de publication
Date de publication:
01 Jan 2020
01 Jan 2020
Historique:
received:
23
08
2019
revised:
02
11
2019
accepted:
03
11
2019
entrez:
1
1
2020
pubmed:
1
1
2020
medline:
1
1
2020
Statut:
ppublish
Résumé
This study examined the effects of gabexate mesilate on spinal nerve ligation (SNL)-induced neuropathic pain. To confirm the involvement of gabexate mesilate on neuroinflammation, we focused on the activation of nuclear factor-κB (NF-κB) and consequent the expression of proinflammatory cytokines and inducible nitric oxide synthase (iNOS). Male Sprague-Dawley rats were used for the study. After randomization into three groups: the sham-operation group, vehicle-treated group (administered normal saline as a control), and the gabexate group (administered gabexate mesilate 20 mg/kg), SNL was performed. At the 3rd day, mechanical allodynia was confirmed using von Frey filaments, and drugs were administered intraperitoneally daily according to the group. The paw withdrawal threshold (PWT) was examined on the 3rd, 7th, and 14th day. The expressions of p65 subunit of NF-κB, interleukin (IL)-1, IL-6, tumor necrosis factor-α, and iNOS were evaluated on the 7th and 14th day following SNL. The PWT was significantly higher in the gabexate group compared with the vehicle-treated group ( Gabexate mesilate increased PWT after SNL and attenuate the progress of mechanical allodynia. These results seem to be involved with the anti-inflammatory effect of gabexate mesilate via inhibition of NF-κB, proinflammatory cytokines, and nitric oxide.
Sections du résumé
BACKGROUND
BACKGROUND
This study examined the effects of gabexate mesilate on spinal nerve ligation (SNL)-induced neuropathic pain. To confirm the involvement of gabexate mesilate on neuroinflammation, we focused on the activation of nuclear factor-κB (NF-κB) and consequent the expression of proinflammatory cytokines and inducible nitric oxide synthase (iNOS).
METHODS
METHODS
Male Sprague-Dawley rats were used for the study. After randomization into three groups: the sham-operation group, vehicle-treated group (administered normal saline as a control), and the gabexate group (administered gabexate mesilate 20 mg/kg), SNL was performed. At the 3rd day, mechanical allodynia was confirmed using von Frey filaments, and drugs were administered intraperitoneally daily according to the group. The paw withdrawal threshold (PWT) was examined on the 3rd, 7th, and 14th day. The expressions of p65 subunit of NF-κB, interleukin (IL)-1, IL-6, tumor necrosis factor-α, and iNOS were evaluated on the 7th and 14th day following SNL.
RESULTS
RESULTS
The PWT was significantly higher in the gabexate group compared with the vehicle-treated group (
CONCLUSIONS
CONCLUSIONS
Gabexate mesilate increased PWT after SNL and attenuate the progress of mechanical allodynia. These results seem to be involved with the anti-inflammatory effect of gabexate mesilate via inhibition of NF-κB, proinflammatory cytokines, and nitric oxide.
Identifiants
pubmed: 31888315
pii: kjp.2020.33.1.30
doi: 10.3344/kjp.2020.33.1.30
pmc: PMC6944363
doi:
Types de publication
Journal Article
Langues
eng
Pagination
30-39Références
Neurosci Lett. 1999 Jul 23;270(1):25-8
pubmed: 10454137
Ann Neurosci. 2012 Jul;19(3):125-32
pubmed: 25205985
Methods Mol Med. 2004;99:35-45
pubmed: 15131327
Korean J Pain. 2013 Oct;26(4):356-60
pubmed: 24156001
Neurosci Lett. 2001 Sep 14;310(2-3):113-6
pubmed: 11585580
Brain Res. 1998 May 11;792(2):263-70
pubmed: 9593928
Pain. 1992 Sep;50(3):355-63
pubmed: 1333581
Pain. 1996 Aug;66(2-3):331-41
pubmed: 8880857
Pain. 2005 Aug;116(3):257-63
pubmed: 15964142
J Neurosci. 2009 Apr 1;29(13):4096-108
pubmed: 19339605
Pain. 1983 Jun;16(2):109-10
pubmed: 6877845
Neuroreport. 2004 Dec 22;15(18):2807-11
pubmed: 15597059
J Pain Res. 2018 Aug 10;11:1511-1519
pubmed: 30127635
Anesth Analg. 2007 Sep;105(3):838-47
pubmed: 17717248
Brain Res Rev. 2006 Aug;51(2):240-64
pubmed: 16388853
Int J Mol Med. 2018 Dec;42(6):3209-3219
pubmed: 30221670
Pain Pract. 2004 Mar;4(1):11-8
pubmed: 17129298
Front Neurosci. 2009 Sep 15;3(2):175-81
pubmed: 20011139
Eur J Neurosci. 2004 Jun;19(12):3375-81
pubmed: 15217394
Biochem Biophys Res Commun. 1998 May 19;246(2):453-6
pubmed: 9610382
J Neurosci. 2002 Apr 15;22(8):3052-60
pubmed: 11943808
Eur J Pain. 2002;6(1):25-34
pubmed: 11888225
Neurochem Res. 2016 Nov;41(11):3042-3051
pubmed: 27485712
J Neurosci. 2015 Dec 16;35(50):16545-60
pubmed: 26674878
Brain Behav Immun. 2015 Oct;49:119-29
pubmed: 25957028
J Neuroimmunol. 2010 Dec 15;229(1-2):26-50
pubmed: 20870295
J Neurosci Methods. 1994 Jul;53(1):55-63
pubmed: 7990513
Neurosci Lett. 2015 Mar 17;590:150-5
pubmed: 25643619
J Exp Med. 2005 Jul 4;202(1):145-56
pubmed: 15998793
Br J Pharmacol. 2008 Jan;153(2):319-34
pubmed: 17994113
Pain. 2007 Oct;131(3):262-71
pubmed: 17317010
Neurosci Lett. 2008 Jun 6;437(3):194-8
pubmed: 18403115
Front Physiol. 2018 Feb 14;9:95
pubmed: 29491840
Mol Pain. 2016 May 12;12:null
pubmed: 27175012
J Neuroinflammation. 2010 Apr 16;7:27
pubmed: 20398373
J Neuroimmune Pharmacol. 2013 Mar;8(1):202-11
pubmed: 23242694
Crit Care Med. 1997 May;25(5):874-9
pubmed: 9187610
Front Mol Neurosci. 2015 Dec 18;8:77
pubmed: 26733801
Int Immunopharmacol. 2016 Dec;41:82-89
pubmed: 27821296
Mol Ther. 2007 Apr;15(4):687-697
pubmed: 28192702
Korean J Anesthesiol. 2010 Apr;58(4):334-7
pubmed: 20508788
Immune Netw. 2012 Apr;12(2):41-7
pubmed: 22740789
Pain. 2014 Dec;155(12):2618-29
pubmed: 25267210
Brain Res Bull. 2008 Nov 25;77(5):233-6
pubmed: 18824078
Drug Discov Today. 2006 Jan;11(1-2):8-20
pubmed: 16478686
Cochrane Database Syst Rev. 2017 Apr 21;4:CD011384
pubmed: 28431202
Pain. 1999 Mar;80(1-2):161-70
pubmed: 10204728